Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.

SG&A Expenses: Alnylam vs. Neurocrine Over a Decade

__timestampAlnylam Pharmaceuticals, Inc.Neurocrine Biosciences, Inc.
Wednesday, January 1, 20144452600017986000
Thursday, January 1, 20156061000032480000
Friday, January 1, 20168935400068081000
Sunday, January 1, 2017199365000169906000
Monday, January 1, 2018382359000248932000
Tuesday, January 1, 2019479005000354100000
Wednesday, January 1, 2020588420000433300000
Friday, January 1, 2021620639000583300000
Saturday, January 1, 2022770658000752700000
Sunday, January 1, 2023795646000887600000
Monday, January 1, 20249755260001007200000
Loading chart...

Unleashing the power of data

A Decade of SG&A Expenses: Alnylam Pharmaceuticals vs. Neurocrine Biosciences

In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Alnylam Pharmaceuticals and Neurocrine Biosciences have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive expansion and marketing strategies. In contrast, Neurocrine's expenses increased by nearly 4,800%, indicating a robust investment in administrative and sales operations.

By 2023, Neurocrine's SG&A expenses slightly surpassed Alnylam's, marking a pivotal shift in their financial dynamics. This trend highlights the evolving priorities and growth strategies of these biotech giants. As the industry continues to innovate, monitoring such financial metrics provides valuable insights into the operational focus and market positioning of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025